Akebia Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AKBA Nasdaq 2834 https://akebia.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Akebia Therapeutics Inc

Akebia Therapeutics Provides Update on Regulatory Process for Vadadustat - Mar 30th, 2023 12:30 pm
Akebia Therapeutics Files Revised Definitive Proxy Statement for Special Stockholder Meeting - Mar 24th, 2023 12:30 pm
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2022 Earnings Call Transcript - Mar 13th, 2023 6:51 am
Q4 2022 Akebia Therapeutics Inc Earnings Call - Mar 10th, 2023 3:42 am
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates - Mar 9th, 2023 1:45 pm
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights - Mar 9th, 2023 12:30 pm
Akebia Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Discuss Recent Business Highlights - Mar 2nd, 2023 1:30 pm
Akebia Receives Positive CHMP Opinion in Europe for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis - Feb 23rd, 2023 9:05 pm
The Petri Dish: Blindness drug approved; Moderna strikes gene-editing deal - Feb 23rd, 2023 10:34 am
Akebia Therapeutics Received Interim Response from the FDA to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease - Feb 21st, 2023 11:30 am
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 1st, 2023 9:05 pm
Akebia Therapeutics Received Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDA - Dec 22nd, 2022 1:45 pm
Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference - Nov 22nd, 2022 9:05 pm
Akebia Therapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags - Nov 9th, 2022 11:10 am
Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates - Nov 3rd, 2022 10:45 pm
Akebia Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights - Nov 3rd, 2022 8:05 pm
Akebia Therapeutics to Report Third Quarter Financial Results and Highlight Recent Company Milestones - Oct 27th, 2022 12:30 pm
Akebia Therapeutics Announces Poster Presentation at ASN Kidney Week 2022 - Oct 21st, 2022 12:30 pm
Akebia Therapeutics to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference - Sep 1st, 2022 12:30 pm
Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study - Aug 5th, 2022 3:12 pm